연구성과로 돌아가기
2020 연구자 정보 (342 / 997)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Kang, Yoon-Koo (Kang, YK) |
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea |
ABL-4264-2022 Kang, Yoon-Koo |
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data [JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial |
SCIE | 1.9 |
GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY ONCOLOGY |
nboku@ncc.go.jp; dcatenac@bsd.uchicago.edu; |
||
|
Kato, Ken (Kato, K) |
Natl Canc Ctr, Div Gastrointestinal Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan Natl Canc Ctr, Div Gastrointestinal Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo, Japan |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; | ||
|
Ki Kang, Won (Kang, WK) |
Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Dept Med,Sch Med, Seoul, South Korea |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; | ||
|
Kim, Jang-Seong (Kim, JS) |
KRIBB, Daejeon, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Kim, V. Narry (Kim, VN) |
Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Kim, Woo-Ho (Kim, WH) |
Seoul Natl Univ, Dept Pathol, Coll Med, Seoul, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Kong, Seong-Ho (Kong, SH) |
Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Lee, Hyuk-Joon (Lee, HJ) |
Seoul Natl Univ, Coll Med, Canc Res Inst, 101 Daehak Ro, Seoul, South Korea Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Lee, Keun-Wook (Lee, KW) |
Seoul Natl Univ, Bundang Hosp, Div Hematol & Oncol, Dept Internal Med,Coll Med, Seongnam, South Korea Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Seongnam, South Korea Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea |
JQV-8143-2023 Lee, Juhyung |
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data [JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial |
SCIE | 1.9 |
GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY ONCOLOGY |
nboku@ncc.go.jp; dcatenac@bsd.uchicago.edu; |
||
|
Min, Jeong-Ki (Min, JK) |
KRIBB, Daejeon, South Korea |
|
|
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | ||
|
Min, Jimin (Min, JM) |
제1저자 |
Seoul Natl Univ, Coll Med, Canc Res Inst, 101 Daehak Ro, Seoul, South Korea Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37212 USA Vanderbilt Univ, Sch Med, Epithelial Biol Ctr, Med Ctr, MRB 4 10435F,2213 Garland Ave, Nashville, TN 37232 USA |
|
0000-0002-2309-7875 Min, Jimin |
[JCR상위 17.6] microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2 | SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | eunyoung.choi@vumc.org;jim.goldenring@vumc.org;hkyang@snu.ac.kr; | |
|
Minashi, Keiko (Minashi, K) |
Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; | ||
|
Muro, Kei (Muro, K) |
Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; | ||
|
Oh, Do-Youn (Oh, DY) |
Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Internal Med,Coll Med, Seoul, South Korea Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; | ||
|
Ryu, Min-Hee (Ryu, MH) |
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea |
|
|
[JCR상위 17.6] Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [JCR상위 17.6] A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data |
SCIE | 17.6 | GASTROENTEROLOGY & HEPATOLOGY;ONCOLOGY | nboku@ncc.go.jp; |
페이지 이동: